Jianming Xu
The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China · Chinese PLA General Hospital · The First Medical Center of Chinese PLA General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jianming Xu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06505395 · A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · recruiting · Gastrointestinal Neuroendocrine Pancreatic Tumor · study chair
- Ph1NCT06468098 · A Study of IBI363 in Subjects With Advanced MalignanciesInnovent Biologics (Suzhou) Co. Ltd. · recruiting · Advanced Malignancies · principal investigator
- Ph3NCT06432296 · Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific AntibodyWuhan YZY Biopharma Co., Ltd. · active not recruiting · Malignant Ascites · principal investigator
- Ph2NCT06266091 · Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific AntibodyWuhan YZY Biopharma Co., Ltd. · completed · Malignant Ascites · principal investigator
- Ph2NCT06158516 · A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine TumorsChanghai Hospital · terminated · Pancreatic Neuroendocrine Tumor · principal investigator
- Ph1NCT05946226 · A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System TumorsSuzhou Immunofoco Biotechnology Co., Ltd · unknown · Advanced Digestive System Tumor · principal investigator
- N/ANCT05940181 · A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumorsjianming xu · unknown · Solid Tumor · principal investigator
- Ph2NCT05879055 · A Study of PM8002 in Combination With Chemotherapy in Patients With NENBiotheus Inc. · active not recruiting · Neuroendocrine Neoplasm · principal investigator
- Ph1NCT05522309 · FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid TumorsEtern BioPharma (Shanghai) Co., Ltd · unknown · Advanced Solid Tumor · principal investigator
- Ph3NCT05459844 · A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETsSinotau Pharmaceutical Group · active not recruiting · Neuroendocrine Tumors · principal investigator
- Early Ph1NCT05275062 · Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic AdenocarcinomaBeijing Immunochina Medical Science & Technology Co., Ltd. · unknown · Advanced Solid Tumors, Gastric Cancer, Esophagogastric Junction Cancer · principal investigator
- N/ANCT05192460 · Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancerjianming xu · unknown · Gastric Cancer, Esophageal Cancer, Liver Cancer · principal investigator
- Ph1NCT05191667 · AN0025 and Chemoradiotherapy Combination in Esophageal CancerAdlai Nortye Biopharma Co., Ltd. · suspended · Esophageal Cancer · principal investigator
- Ph1/Ph2NCT05142423 · A Study of AK109 Combined With AK104 in Patients With Advanced Solid TumorsAkeso · recruiting · Advanced Solid Tumor · principal investigator
- Ph1NCT04998422 · A Study of HG381 Administered to Patients With Advanced Solid TumorsHitGen Inc. · recruiting · Advanced Solid Tumor · principal investigator
- Ph1/Ph2NCT04699643 · FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid TumorsEverNov Medicines (Zhuhai Hengqin) Co., Ltd · unknown · Advanced Solid Tumors · principal investigator
- Ph1/Ph2NCT04601610 · KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular CarcinomaJiangsu Alphamab Biopharmaceuticals Co., Ltd · terminated · Advanced HCC · principal investigator
- Ph1NCT04501744 · A Study of M701 (EpCAM and CD3) in Malignant AscitesWuhan YZY Biopharma Co., Ltd. · completed · Malignant Ascites, Cancer · principal investigator
- Ph3NCT04415853 · Study of Larotinib in Unresectable Advanced or Recurrent Esophageal CancerSunshine Lake Pharma Co., Ltd. · recruiting · Esophageal Cancer · principal investigator
- Ph3NCT04409223 · Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of ImatinibJiangsu HengRui Medicine Co., Ltd. · terminated · Gastrointestinal Stromal Tumors · principal investigator
- Ph2/Ph3NCT04353375 · HMPL-453 Tartrate in Advanced Intrahepatic CholangiocarcinomaHutchmed · recruiting · Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult · principal investigator
- Ph3NCT04342910 · Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJCJiangsu HengRui Medicine Co., Ltd. · recruiting · Gastric Cancer · principal investigator
- Ph1/Ph2NCT03888092 · Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene AmplificationSunshine Lake Pharma Co., Ltd. · completed · Esophageal Squamous Cell Carcinoma · principal investigator
- Ph1NCT03692520 · Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid TumorsSinocelltech Ltd. · unknown · Advanced Solid Tumors · principal investigator
- Ph1NCT03356158 · A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal CancerSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · unknown · Metastatic Colorectal Cancer · principal investigator
- Ph1NCT03101488 · Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors3D Medicines (Sichuan) Co., Ltd. · completed · Solid Tumors · principal investigator
- Ph2NCT02966821 · Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract CarcinomaHutchison Medipharma Limited · completed · Biliary Tract Cancer · principal investigator
- Ph1/Ph2NCT02489201 · A Study of Donafenib Monotherapy in Advanced Oesophageal CancerSuzhou Zelgen Biopharmaceuticals Co.,Ltd · terminated · Oesophageal Cancer · principal investigator
- Ph1NCT02430311 · The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.AstraZeneca · completed · Advanced Solid Tumours · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 9 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:50 UTC. The ranking covers the 200 most relevant of 1732 PubMed records, and a shared surname and initials can bring in a namesake. All 1732 on PubMed
- 778 citationsRCR 69.3
- 476 citationsRCR 40.5
- Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial.Lancet Gastroenterol Hepatol · 2022452 citationsRCR 48.7
- 392 citationsRCR 33.0
- 358 citationsRCR 42.9
- 335 citationsRCR 41.3
- 329 citationsRCR 19.5
- 309 citationsRCR 23.8
- 139 citationsRCR 51.7
- 128 citationsRCR 7.4